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drugs taken, and the pain rating at baseline and at 2 and 4 hours after the first dose. Those who successfully completed the first phase started the second phase of the study, in which migraine attacks were treated with sumatriptan for up to 6 months. Other details of the study design and methods of outcome assessment were not reported.
Analysis of effectiveness
The outcome measures used in the analysis were a set of probability values that were subsequently in the decision model. The following probabilities were considered: resolution within 2 hours; use of rescue therapy if resolution was not achieved within 2 hours; resolution with rescue therapy; resolution without rescue therapy; and physician office visit and emergency room visits (in the case of no resolution).
Productive time lost due to migraine was also estimated for resolution after 2 or 4 hours. No further information on the analysis of effectiveness was provided.
Effectiveness results
The estimated probability values with sumatriptan and usual therapy, respectively, were: 0.47 (sumatriptan) versus 0.09 (usual therapy) for resolution within 2 hours; 0.2453 (sumatriptan) versus 0.5055 (usual therapy) for the use of rescue therapy if resolution was not achieved within 2 hours; 0.96 (sumatriptan) versus 0.1733 (usual therapy) for resolution with rescue therapy; 0.3125 (sumatriptan) versus 0.1778 (usual therapy) for resolution without rescue therapy; 0.0439 (sumatriptan) versus 0.0276 (usual therapy) for physician office visit (in the case of no resolution); and 0.0044 (sumatriptan) versus 0.0052 (usual therapy) for emergency room visits (in the case of no resolution).
Productive time lost due to migraine was 38.6 minutes for resolution after 2 hours and 77.2 minutes for resolution after 4 hours.
Clinical conclusions
The effectiveness results suggested that sumatriptan was more effective (higher resolution rates) than usual therapy for the treatment of migraine. These values were used in the decision model.
Modelling
A model, based on a decision tree, was used to represent treatment alternatives and the possible outcomes of migraine treatment. After a migraine attack, the patient was offered sumatriptan or usual therapy and the two branches of the tree were similar. Nine possible, mutually exclusive outcomes were considered in the decision tree on the basis of the following six situations: migraine is resolved (pain free) 2 hours after the first dose of treatment; the patients received a second rescue dose of the same treatment if migraine was not resolved;
migraine was resolved within 4 hours of the first dose;
patients whose pain was not resolved visited a primary care doctor for further treatment; or went to an emergency room; or did not seek further medical care.
The model appears to have been deterministic.
Methods used to derive estimates of effectiveness
The authors made some assumptions that were used in the decision model.
Estimates of effectiveness and key assumptions
Some of the assumptions made in the model were as follows:
sumatriptan 50 mg was considered comparable to sumatriptan 100 mg in terms of efficacy;
the patient's productivity depended on the resolution of migraine within the first 4 hours of treatment;
rescue therapy 2 hours after the failure of the first therapy did not change the 4-hour resolution rate;
the maximum productivity loss for each migraine attack was 1 day's wages based on an 8-hour workday, given that most migraine attacks resolve within 24 hours; and productivity loss with usual therapy was assumed to be equal to that of sumatriptan.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic analysis was the economic benefit associated with the patient's ability to return to work after the migraine attack. This was estimated using the human capital approach, the treatment benefits being quantified by applying the national wage rate to a patient's productivity (assessed by productive working hours) after receiving migraine treatment. A modelling approach was used to assess the estimated benefits. A range of 0.4 to 1.5 migraine attacks per month, as reported in the epidemiological study, was considered. No discounting was applied.
Direct costs
Discounting was not relevant since the costs were incurred during a short time. The unit costs and the quantities of resources used were reported separately. The health services included in the economic analysis were sumatriptan, non-5HT1 agonists (usual therapy), physician office visits and emergency room visits. The cost/resource boundary reflected the societal perspective adopted in the study. The costs were estimated based on the average wholesale prices for non-5HT1 drugs (weighting the cost of each nontriptan agent by its rate of use as reported in the clinical trial and market share data) and on an administrative claims data analysis performed between 1989 and 1990 for visits to emergency room and physician offices. Resource consumption was derived from actual data estimated in a double-blind clinical trial. Some assumptions were also made. All of the costs were inflated to 1998 prices using the medical care component of the Consumer Price Index.
